Dr. Subrata Kumar Pore
Associate Professor & Ramalingaswami Fellow

Specialization: Cancer Biology, Targeted Liposomal Drug Delivery, Peptides, Micro-RNA, Breast Cancer Bone Metastasis

Email: skpore@amity.edu; subratapb@gmail.com

Dr. Pore obtained his Ph.D. from CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad in 2015. He started his postdoctoral research at the University of Pittsburgh Medical Centre (UPMC), University of Pittsburgh, USA from Feb 2014 before the final Ph.D. degree was conferred. His Ph.D. work was focused on the development of biomaterials for targeted anticancer therapeutics using an artificial microRNA against Hsp90 protein. During postdoctoral research, his main objective was to show the inhibitory roles of dietary phytochemicals in breast cancer-induced bone metastasis and bone loss. In Dec 2018, Dr. Pore was awarded the Ramalingswami Fellowship by the Dept. of Biotechnology and had joined IASST-Guwahati in July 2019. He moved to the Amity Institute of Molecular Medicine & Stem Cell Research, Amity University Uttar Pradesh in July 2020. His current research is focused on the development of peptide-based liposomal nanocarriers for targeted anticancer therapeutics in breast cancer. Apart from research, he is actively involved in teaching at undergraduate and postgraduate levels.

Number of Publication: 21

Current Running Project: 1 (*Development of Hsp90-Regulating microRNA-based Therapeutics for Breast Cancer*, Department of Biotechnology, July 2019 - June2024)

Fellowships and Awards:

- Ramalingaswami Fellowship, Department of Biotechnology, Govt. of India, 2019
- 'Scholar-In-Training Award' from AACR-2016
- 'Basic Science Symposium Travel Award' AUA-2014
- CSIR-NET, Govt. of India, Dec 2006
- Indian Academy of Science Fellowship, May 2006

Selected publications:

1. **Subrata K Pore**, Hahm ER, Kim S, Singh KB, Nyiranshuti L, Latoche JD, Anderson CJ, Adamik J, Galson DL, Weiss KR, Watters RJ, Lee B, Kumta PN, and Singh SV. *A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption*. ***Molecular Cancer Therapeutics*** 2020, 19(2), 420-431 (Impact factor: 4.9)
2. **Subrata K Pore***, Ganguly A, Sau S, Godeshala S, Kanugula AK, Ummanni R, Kotamraju S, and Banerjee R*. *N-end rule pathway inhibitor sensitizes cancer cells to antineoplastic agents by regulating XIAP and RAD21 protein expression*. ***J Cell. Biochem.*** 2020, 121(1), 804-815 *corresponding author (Impact factor: 3.5)
3. **Subrata K Pore**, Hahm ER, Latoche JD, Anderson CJ, Shuai Y, and Singh SV. *Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate*. ***Carcinogenesis*** 2018, 39(2):134-145 (Impact Factor: 5.1)
4. **Subrata K Pore**, Choudhary A, Rathore B, Ganguly A, Sujitha P, Kumar CG, Agawane SB, Kumar JM, Scaria V, Pillai B and Banerjee R. *Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect*. ***Biomaterials*** 2013, 34(28):6804-6817 (Impact Factor: 10.3)
5. Jiang Y#, **Subrata K Pore#**, Lee JH, Sriram S, Mai BK, Han DH, Zakrzewska A, Kim Y, Banerjee R, Lee S and Lee MJ. *Characterization of mammalian N-degrons and development of heterovalent inhibitors of the N-end rule pathway*. ***Chemical Science*** 2013, 4:3339-3346. (#Equal contribution) (Impact Factor: 8.7)
6. Kashyap M#, **Subrata K Pore#**, Chancellor M, Yoshimura N, Tyagi P. *Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor*. ***Life Sci.*** 2016, 167:98-104 (#Equal contribution) (Impact Factor: 2.7)